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Abstract
Background: Despite concerns about affordability and sustainability, many models of the lifetime costs of
antiretroviral therapy (ART) used in resource limited settings are based on data from small research cohorts,
together with pragmatic assumptions about life-expectancy. This paper revisits these modelling assumptions in
order to provide input to future attempts to model the lifetime costs and the costs of scaling up ART.
Methods: We analysed the determinants of costs and outcomes in patients receiving ART in line with standard
World Health Organization (WHO) guidelines for resource poor settings in a private sector managed ART
programme in South Africa. The cohort included over 5,000 patients with up to 4 years (median 19 months) on
ART. Generalized linear and Cox proportional hazards regression models were used to establish cost and outcome
determinants respectively.
Results: The key variables associated with changes in mean monthly costs were: being on the second line
regimen; receiving ART from 4 months prior to 4 months post treatment initiation; having a recent or current CD4
count <50 cells/µL or 50-199 cells/µl; having mean ART adherence <75% as determined by monthly pharmacy refill
data; and having a current or recent viral load >100,000 copies/mL. In terms of the likelihood of dying, the key
variables were: baseline CD4 count<50 cells/µl (particularly during the first 4 months on treatment); current CD4
count <50 cells/µl and 50-199 cells/µl (particularly during later periods on treatment); and being on the second
line regimen. Being poorly adherent and having an unsuppressed viral load was also associated with a higher
likelihood of dying.
Conclusions: While there are many unknowns associated with modelling the resources needed to scale-up ART,
our analysis has suggested a number of key variables which can be used to improve the state of the art of
modelling ART. While the magnitude of the effects associated with these variables would be likely to differ in other
settings, the variables influencing costs and survival are likely to be generalizable. This is of direct relevance to
those concerned about assessing the long-term costs and sustainability of expanded access to ART.
Introduction
With access to antiretroviral therapy (ART) now rapidly
expanding in low and middle-income countries, atten-
tion is increasingly turning to the affordability and sus-
tainability of these programmes [1]. Given the potential
effectiveness of treatment coupled with the scale of the
response needed, it is important that planning takes a
long term perspective. W h i l em a n ys t u d i e sh a v e
focussed on the effectiveness of ART in resource-limited
settings, cost studies are limited, especially those docu-
menting costs in routine and established programmes
and over longer periods of time. In recent years, the
management of ART programmes in low and middle
income countries has increasingly conformed to the
World Health Organization (WHO) guidelines for
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for when to start ART based on the patient’s CD4 count
or WHO stage, guidelines for monitoring ART as well
as guidelines regarding which antiretrovirals (ARVs)
should be administered within distinct first and second
line regimens. These guidelines therefore provide a good
framework for understanding disease progression and
the costs of patients in ART programmes.
Because ART has only recently been available in
resource-limited settings, lifetime costs – ak e yi n p u t
into the costs of scaling up - are calculated through
extrapolating primary data, with the Markov model
being the most common framework used for this extra-
polation. Many models include the baseline and current
CD4+ cell count (i.e. the most recent test value), viral
load and WHO staging, but other potential determi-
nants of costs such as adherence have been excluded.
This raises questions of the accuracy of the resulting
estimates which could have implications for attempts to
plan for expanded access to ART.
A Markov model consists of a number of mutually
exclusive and collectively exhaustive Markov states, with
at least one of these being an “absorbing state” (e.g.
death). Patients remain in each state for an equal incre-
ment of time, called a Markov cycle, before being
allowed the option of moving to a different state (or
staying in the current state) as determined by one or
more transition probabilities. In addition to time (or
survival) increments, health care costs are attached to
each state. Over a large number of cycles, lifetime costs
and life expectancy is estimated [3,4].
To establish appropriate Markov states it is thus
necessary to estimate which variables have a sizeable
impact on the costs associated with being in a state
together with the transition probabilities determining
movements between states. While many types of transi-
tion probabilities are possible, the most important is the
probability of dying as this determines overall life expec-
tancy. Because the majority of the costs of ART are
associated with ARV drugs, accurate calculation of life
expectancy is crucial for the estimation of lifetime costs
which in turn is a key input into calculations of the
costs of scaling up [5].
This paper seeks to identify the variables that have an
impact on direct health care costs and the likelihood of
dying with a view to informing the development of Mar-
kov models for estimating lifetime costs and the costs of
scaling up ART in resource-limited settings. We initially
review the ART Markov model and cost determinant lit-
erature to establish the variables and variable categories
that have been used to date. Thereafter, we assess the
importance of these through the analysis of a large
cohort from a private health care disease management
programme. While this analysis would ideally be
conducted using data from individuals receiving ART in
a range of routine models of care, including those found
in the public health care sector, these routine data are
not available. We have attempted to improve the gener-
alisability of our findings by restricting our analysis to
those patients in the private disease management pro-
gramme that receive ART in line with the WHO guide-
lines for resource-limited settings [2].
Methods
Literature review
Our literature review included all cost, cost-effectiveness
and cost-utility analyses of HIV-treatment including
ART in resource-poor settings. While most economic
analyses of ART focus on the annual per patient cost or
the cost per specified outcome measure (e.g. per patient
virally suppressed), we restricted our review to studies
that had used Markov modelling to extrapolate available
data to calculate lifetime costs and life expectancy. The
reason for this is that the life expectancy of a patient on
ART is a key determinant of lifetime costs and of the
number of patients surviving and remaining in care over
a n yp r o j e c t i o np e r i o d ;i ti st h e r e f o r eo n eo ft h em o s t
important inputs into any estimation of the costs of
scaling up. A previous study by our group showed that
20% more patients would be remaining in care after a
scale-up period of 10 years if life expectancy on ART of
13 years were assumed instead of 8.5 years [6]. However,
we also included studies that attempted to ascertain the
variables influencing costs over shorter time frames
g i v e nt h a tt h e s ec o u l dp r o v i d ei n p u ti n t ot h ec o n s t r u c -
tion of Markov states. A Pubmed search using the key-
words “cost”, “resource-poor”, “low-income country/
countries”, “middle-income country/countries”, “devel-
oping” and “antiretroviral” was conducted for all papers
published before 1 May 2009.
Model comparison and refinement
Data source
The determinants of costs and survival on ART were
evaluated using a large database of patients enrolled
with Aid for AIDS (AfA), a group that manages HIV-
related care for a number of medical insurance funds in
the private health care sector in Southern Africa. Aid
for AIDS does not manage patients directly, but rather
provides guidelines for private medical practitioners’
care of its participants and reimburses claims. Medical
care is provided via patients’ own general practitioner,
therefore there are no formal “sites” but rather several
thousand general practitioners and specialist practices
taking care of patients, including those participating
in Aid for AIDS. Treatment is funded by contracted
companies or medical aid funds (composed of
pooled monthly contributions from members) which
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not related to HIV. Data collected by AfA include
demographics and previous medical history, CD4+ cell
count, viral load and claims (including ART dispensing
data). These claims are captured monthly by AfA from
the medical insurance funds, pathology laboratories or
from the patients or treating doctors directly using rou-
tine electronic administrative systems. Claim reimburse-
ment is subject to established AfA protocols, including
protocols for ART initiation, change of ART regimen,
and the treatment of certain opportunistic infections.
Despite this being a private sector programme, antire-
troviral guidelines are similar in many respects to WHO
guidelines for resource-poor settings as well as
the South African public sector guidelines [2,7]. The
recommended initial regimen is a combination of two
nucleoside reverse transcriptase inhibitors (NRTIs) and
a non-nucleoside reverse transcriptase inhibitor
(NNRTI). Second line therapy consists of a boosted pro-
tease inhibitor (PI) with two NRTIs. Health services pro-
vided for patients within AfA include additional primary
care doctor visits for patients that have exceeded their
routine medical insurance benefits, telephonic counsel-
ling services and antiretroviral drugs dispensed monthly
from private pharmacies or delivered via courier to the
patient’s home. While ART can be initiated at CD4
<350 cells/µL rather than CD4 <200 cells/µL, we
restricted the analysis to the latter group as this is the
more common starting criterion in resource poor set-
tings, including the South African public sector at the
time of this study (these guidelines have recently been
revised to recommend ART initiation at CD4 <350
cells/µL [8]). Furthermore, we only included patients
starting ART with a NNRTI plus two NRTIs, as recom-
mended by the WHO for resource-limited settings [2].
We determined average adherence to ART using
monthly pharmacy refill data. This approach has been
shown to correlate well with adherence assessment by
therapeutic drug levels [9,10], and has been found to
reliably predict virologic suppression [11], development
of HIV drug resistance [12], and survival [13]. Previous
analyses of these AfA data have in addition shown that
this measure of adherence is a determinant of costs
[14,15]. We expressed pharmacy claim adherence as a
percentage and calculated it as the number of months
with ART claims submitted divided by the number of
complete months from ART initiation to death, withdra-
wal from the Aid for AIDS program, or study end.
Two of the medical insurance funds that contract AfA
were selected on the grounds that they had large
numbersof patients, similar treatment benefits, and no
co-payment for ART. This allowed us to describe deter-
minants of costs and outcomes without biases associated
with the patient’s ability to pay, which has been reported
to influence access to health care and outcomes on ART
[16,17]. Patients were included in the study if they were
ART naïve at entry (the exception being women who
had received prophylaxis for prevention of mother-to-
child transmission), adult (19 years or older at the time
of approval for ART) and if ART was started between
November 1998 and November 2007.
Direct health care costs were analysed from the provi-
der’s perspective. The tariff amount was used as a proxy
for these costs, as opposed to the amount charged by
the provider. This is because providers may charge dif-
ferent rates for services with the same tariff code. The
use of the tariff rate allows for the same cost to be
assumed for the same type of service.
The prices of antiretroviral drugs have fallen dramati-
cally over the past ten years. To account for this we
deflated ARV prices to the April 2007 level. All other
health care costs have increased; these were inflated to
the April 2007 level using the Consumer Price Index
net of mortgage payments (CPIX) [18]. The average
South African Rand to United States Dollar (US$)
exchange rate in April 2007 (R7.14 to US$1) was used
to convert costs to US$ equivalents [19].
Establishment of Markov states
As the distribution of mean health care costs was right-
skewed in our data, ordinary least squares regression
was not appropriate [20,21]. Generalised linear regres-
sion models (GLM) have been proposed as they deter-
mine the impact of variables on the arithmetic mean
and thus provide a method for identifying variables
strongly associated with varied costs [20]. A GLM with
a log-link function and a gamma distribution described
the trends in the data well. To account for multiple
measures within an individual as well as potentially
strong correlations between the variables, we used gen-
eralised estimated equations with an unstructured corre-
lation matrix. Variable coefficients and their 95%
confidence intervals were determined using robust stan-
dard errors and the model fit was evaluated using
deviance residuals [20].
Multiple Cox proportional hazard regression analysis
was used to identify variables associated with a likelihood
of dying. Based on the findings of both the cost and out-
come analyses, a pragmatic decision on which Markov
states to include in the final model is needed; as the
number of states increases, so the model complexity
increases exponentially. Data storage, basic calculations
and data extraction was handled in Microsoft Sequel Ser-
ver 2008. Statistical analysis was performed in Stata 10.
Ethics statement
The study was approved by the Research Ethics Com-
mittee, University of Cape Town and by the Board of
Directors of Aid for Aids. All patients signed consent
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database.
Results
Existing models in literature
Over 300 cost, cost-effectiveness and cost-utility ana-
lyses of ART were found via a Pubmed search, but these
included only 6 different Markov models of ART in low
and middle income countries, some of which were used
in more than one publication [6,22-27]. A number of
variables were used in these studies to define Markov
states, as outlined in Table 1. These included the base-
line (i.e. pre-ART) CD4 count category, the current
CD4 count category, baseline and current viral load
categories, time on ART, being on a first or second line
ARV regimen, opportunistic infections or WHO staging;
and adverse events on ART. These variables could be
combined in a variety of ways to create distinct Markov
states depending on the model.
Model comparison and refinement
Dataset
The characteristics of the cohort are described in
Table 2. After exclusions, 5,177 patients met our eligibil-
ity criteria, with over 136,600 patient months of obser-
vation, about half of which were on ART. Median
follow-up on ART was 19 months (IQR: 10 to 32). The
proportion of patients who left the medical insurance
fund was 34%. These patients either changed their
employment, switched to a different medical insurance
scheme or voluntarily stopped their contributions to the
insurance scheme. The most common first line antire-
troviral regimen was zidovudine/lamivudine/efavirenz
(65 %). Lopinavir/ritonavir/zidovudine/didanosine was
the most common second line regimen. CD4 and viral
load monitoring was done 1.5 times per annum on
average.
Markov states
To determine the most important variables on which to
base Markov states, we assessed whether variables had a
sizeable effect on costs or on the likelihood of dying.
The literature review identified a number of differences
in the ways that variables were categorised. Using the
categories described in the literature as a starting point,
we determined the most appropriate categories for the
variables in our dataset guidedb yr e s i d u a ld i a g n o s t i c s ,
whether overall model fit improved with a changed cate-
gorisation, and whether the p-value was significant at
the 95% confidence interval. The variables included in
the analysis were: (1) baseline CD4+ cell count (cate-
gorised as 0-49, 50-199 cells/µL) (following Cleary et al
[6,22] and Goldie et al [25]); (2) current or most recent
(carried forward for up to 12 months) CD4+ cell count
(0-49, 50-199, 200 to 349, 350 to 499, and ≥500 cells/µl)
(similar categories as Bachman [24], Badri et al [23] and
Goldie et al [25]); (3) baseline viral load (categorised
below or above 100,000 copies/ml) (Goldie et al [25]
include this variable, but use far more categories); (4)
Current or most recent viral load (categorised as <400,
400-10,000, 10,000-100,000, >100,000 copies/ml) (Goldie
Table 1 Determinants of Markov states in the literature
Markov
states
defined by:
Bachmann
2006
Badri et al
2006
Cleary et al 2006;
2008
Goldie et al 2006 Marseille
et al
2006
Vijayaraghavan
et al 2007
Baseline CD4
stratum
<200, 200-350,
>350
<50, 50-200 <50; 50-200; 200-500; >500
Current CD4
stratum
<200, 200-350 <200, 200-350,
>350
<50; 50-200; 200-500; >500
Baseline viral
load stratum
>100,000; 30,001-100,000; 10,001-30,000;
3,001-10,000; 501-3,000; 0-500
Current viral
load stratum
>100,000; 30,001-100,000; 10,001-30,000;
3,001-10,000; 501-3,000; 0-500
Suppressed;
unsuppressed
Time on ART 0-3; 3-6; 6-12; 12-24;
24-36; >36 months
First or
second line
ARV regimen
Yes Yes Yes Yes Yes
Disease
staging or
opportunistic
infections
Tuberculosis,
other
opportunistic
infection, no
opportunistic
infection
No-AIDS/ AIDS Severe bacterial infection; severe fungal
infection; severe malaria; tuberculosis;
isosporiasis; cerebral toxoplasmosis;
nontuberculous mycobacteriosis; other
severe opportunistic infection; mild
bacterial infection; mild fungal infection;
other mild infection
WHO
Stages
(1, 2, 3, 4)
AIDS
Adverse
events
Toxicity; no
toxicity
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able, but use different categories); (5) ART regimen
(either first line or second line) (used by all except
Bachman [24]); and (6) time periods relative to ART
initiation (-4 to 4, 4 to 12, 12 to 24, 24 to 48 months on
treatment) (similar to Cleary et al [6,22]). In addition to
the variables identified in the literature, we also consid-
ered: (7) overall adherence, as determined using monthly
pharmacy claim data and divided into quartiles based on
the observed distribution of adherence in the cohort
(<42%, 42%-75%, 75%-92%, >92%); (8) the NNRTI
included in the initial first line regimen (either efavirenz
or nevirapine); (9) the duration of CD4 count monitor-
ing prior to starting ART, a proxy for duration within
pre-ART care (≤6 months and > 6 months); (10) age at
starting ART (<25, 25 to 50 and >50 years old); and (11)
sex. Our data did not allow us to include variables relat-
ing to WHO disease staging, opportunistic infections or
adverse events.
All the variables were included in the analysis explor-
ing the determinants of costs and the likelihood of
dying. In the baseline, the following initial parameter
states were assumed: (1) baseline CD4 cell count
between 50 and 199cells/µL; (2) current CD4+ cell
count between 50 and 199cells/µL; (3) baseline viral
load < 100,000 copies/ml; (4) current viral load < 400
copies/ml; (5) on first line ART; (6) time period 12 to
23 months on ART; (7) overall adherence in the upper
quartile (>75%); (8) NNRTI = efavirenz; (9) >6 months
of CD4 monitoring prior to starting ART; (10) age at
starting ART 25 to 50; and (11) sex = female
The results from the multiple regression analysis of
costs (all variables were included in the model) are
found in Table 3. Mean cost per patient month is pre-
sented for each variable or variable category and is
compared to a reference or baseline which is the mean
cost across all patients and time periods. We found
higher current CD4 counts were associated with lower
costs while having a current viral load above 100,000
copies/ml was associated with increased costs. Being
on efavirenz was more costly than nevirapine, and
being on second line was more costly than being on
first line; these findings are likely to relate to the
higher costs of the ARV drugs in these states as
opposed to other health care costs. Lower adherence
was an important driver of costs, as was time on treat-
ment, with monthly costs in the period from 4 months
before starting ART to 4 months on ART being almost
double the monthly costs thereafter. After this time,
the size and significance of the association between
costs and time on treatment waned dramatically. Fig-
ure 1 illustrates the full set of variables and their influ-
ence on the mean total monthly direct health care
costs relative to the baseline scenario.
The results from the multiple Cox proportional
hazards regression analysis of the likelihood of dying
Table 2 The characteristics of the cohort (IQR = interquartile range)
Total number of patients 5 197
Patient months Overall
On ART
136 672
116 306 (85%)
Duration on ART (months) Median
IQR
19
(10 to 32)
Age at starting ART (years) Median
IQR
37.3 years
(32.4 to 42.9)
Sex Female
Male
6 379 (59.%)
4 356 (41%)
Patient status at end of study period Active
Left the scheme
Dead
2 922 (56%)
1 834 (34%)
421 (8%)
Baseline CD4+ cell count Median
IQR
87 cells/μL
(37 to 145)
Baseline viral load (log10) Median
IQR
5.22
(4.73 to 5.63)
NNRTI used in first line Nevirapine
Efavirenz
2 655 (26%)
6 711 (74%)
NRTI combination in first line Zidovudine + lamivudine
Stavudine + lamivudineother
other
3 339 (65%)
1 225 (24%)
633 (11%)
Duration of CD4+ cell count monitoring before starting ART (months) Median
IQR
1.2
(0.6 to 2.6)
Overall Adherence as measured by monthly pharmacy refill data Median
IQR
74.4%
(38.4 to 92.3)
IQR=Interquartile Range
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compared with the same referent groups as in the cost
analysis, but a separate model was used for each of the
time periods. We found higher current CD4 counts,
higher ART adherence, and current viral loads below
100,000 copies/ml were associated with lower likeli-
hoods of dying across all periods, with baseline values
for CD4 and viral load contributing very little addi-
tional effect after the first 4 months on treatment.
Longer duration of monitoring prior to starting ART
was associated with a lower likelihood of dying in ear-
lier periods and being greater than 50 years or younger
than 25 years at starting ART was associated with a
higher likelihood of dying in later periods. Being on
second line was associated with an increased likelihood
of dying across all periods.
Discussion
We analysed determinants of direct health care costs
and survival in 5,197 HIV-infected adults enrolled in a
South African managed care ART programme with
136,672 patient months of follow-up, spanning -4
months before ART to 4 years on ART. If each Markov
state is defined to include unique combinations of these
variables, thousands of states could be defined. A corre-
spondingly large dataset would then be needed to calcu-
late the costs and transitions associated with each of
these states. For this reason, it becomes necessary to
focus only on variables that have the most marked
effects on costs and outcomes within reasonable confi-
dence intervals. The key variables associated with
changes in mean monthly costs were: being on the sec-
ond line regimen; receiving ART from 4 months prior
Table 3 Multiple generalised linear regression analysis of the determinants of total mean monthly costs (US$)
Variables Value % change from referent p-value
Time period relative to ART initiation (months) -4 to 4 384 (321 to 459) 80% <0.001
4 to 12 238 (204 to 277) 12% 0.158
12 to 24 Referent
24 to 48 222 (182 to 270) 4% 0.705
Baseline CD4 count (cells/µL) 0 to 49 193 (164 to 227) -10% 0.228
50 to 199 Referent
Current CD4 count (cells/µL) 0 to 49 352 (290 to 426) 65% <0.001
50 to 199 Referent
200 to 349 190 (161 to 223) -11% 0.16
350 to 499 166 (141 to 195) -22% 0.002
≥500 158 (123 to 202) -26% 0.017
Baseline viral load (copies/ml) <100 000 Referent
≥100 000 220 (195 to 248) 3% 0.601
Current viral load (copies/ml) <400 Referent
400 to 9 999 219 (191 to 250) 3% 0.717
10 000 to 99 999 195 (164 to 232) -8% 0.317
≥100 000 249 (209 to 296) 17% 0.082
Overall adherence <42% 264 (235 to 297) 24% <0.001
42 to 74% 263 (233 to 295) 23% 0.001
75 to 92% 244 (218 to 273) 14% 0.019
≥92% Referent
ARV regimen First line Referent
Second line 409 (255 to 656) 92% 0.007
NNRTI in first line Nevirapine 197 (182 to 213) -8% 0.042
Efavirenz Referent
Duration of CD4 count monitoring (months) ≤6 181 (161 to 204) -15% 0.008
>6 Referent
Sex Male 206 (188 to 226) -3% 0.463
Female Referent
Age at starting ART (years) <25 194 (164 to 230) -9% 0.282
25 to 50 Referent
>50 230 (194 to 271) 8% 0.384
Referent cost 213 (178 to 256) NA NA
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current CD4 count <50 cells/µL or 50-199 cells/µl; hav-
ing mean ART adherence <75% as determined by
monthly pharmacy refill data; and having a current or
recent viral load >100,000 copies/mL. In terms of the
likelihood of dying, the key variables associated with
changes in survival were: baseline CD4 count<50 cells/µl
(particularly during the first 4 months on treatment);
current CD4 count <50 cells/µl and 50-199 cells/µl (par-
ticularly during later periods on treatment); and being
on the second line regimen. Being poorly adherent and
having an unsuppressed viral load was also associated
with a higher likelihood of dying.
The relationships between these variables and costs
and outcomes were consistent with trends described in
the literature, though the scale did differ in some cases:
lower CD4 count, higher viral load, lower adherence,
and being on second line therapy was associated with
higher costs and worse outcomes. In addition, sub-opti-
mal adherence drives resistance to first line therapy,
leading to second line therapy being initiated. There was
a relative small and limited association between costs
and outcomes and the baseline pathology results (CD4
count and the viral load), most likely due to the current
or most recent CD4 and viral load results being domi-
nant. The finding that lower adherence is associated
with higher costs (in addition to its known effects on
biological variables such as CD4 count and viral load
and starting second line therapy) further supports the
need to include this variable in Markov models.
Based on the above, one would anticipate that Markov
models that use these variables as the bases of their
Markov states may have superior accuracy. However, in
our literature review, the only Markov model that
specified costs and outcomes in relation to duration on
ART was Cleary et al [6,22]. Most of the models sepa-
rated first from second line ART to capture the cost dif-
ferences, but were unable to estimate different survival
transition probabilities because data on outcomes of
patients on second line was limited. Bachmann [24],
Goldie et al [25] and Badri et al [23] all included the
current CD4 count but Cleary et al [6,22] only included
the baseline CD4 count. Baseline and current viral load
w a so n l yi n c l u d e db yG o l d i ee ta l[ 2 5 ] .O p p o r t u n i s t i c
infections or WHO staging were included in all the
models except Cleary et al [6,22]. Unfortunately these
data were not available within the AfA cohort, and we
were therefore unable to assess the importance of these
for the construction of Markov states. None of the mod-
els included sex, ART adherence, age or duration of pre-
ART care.
There are a number of limitations to this analysis.
First, our cohort consisted of private sector patients
when the majority of patients in resource-limited set-
tings are treated in the public or NGO sector. However,
the baseline characteristics of our cohort (CD4+ cell
count, proportion female and age) are comparable with
cohorts from low-income countries [28] and we
restricted our analysis to patients receiving NNRTI-
based first line ART regimens and starting ART at
CD4<200 cells/µl, in keeping with WHO recommenda-
tions for resource-limited settings [2]. While we would
not claim that our actual cost findings are generalisable
to public sector settings or to other countries, we would
argue that the variables that influence costs and out-
comes are likely to be relevant even if the magnitude of
their effects could differ. Second, the impact of specific
opportunistic infections, disease staging or adverse
Figure 1 The influence of variables on mean monthly costs
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analysis as these data were not available. We are there-
fore unable to comment on the validity of this aspect of
some of the Markov models in the literature.
Conclusion
I nc o n c l u s i o n ,w eh a v ea n a lysed the determinants of
direct health care costs and outcomes in a private health
care sector managed ART programme. Our focus has
been to use statistical techniques to determine the key
variables to include in Markov states and to use these
findings to inform future modelling of the costs of scal-
ing up ART. Our results suggest that important drivers
of costs and outcomes include time on ART, being on
first versus second line regimens, the current CD4 cell
count, the current viral load, age at starting ART and
adherence. The inclusion of these variables should be
considered for future modelling of the costs of scaling
up ART programmes.
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Table 4 Multiple Cox proportional hazard regression analysis of the relative risk of dying
Variables 0 to 4 months
on ART
5 to 12 months
on ART
13 to 24 months
on ART
>24 months on
ART
co-eff (95% CI) p-
value
co-eff (95% CI) p-
value
co-eff (95% CI) p-
value
co-eff (95% CI) p-
value
Baseline CD4 cell
count (cells/µL)
<50 2.09 (1.02 to 4.28) 0.043 1.6 (0.84 to 3.06) 0.152 1 (0.57 to 1.73) 0.992 0.79 (0.51 to 1.22) 0.279
50-199 Referent
Current CD4 cell
count (cells/µL)
<50 N/A N/A 1.89 (0.96 to 3.72) 0.065 3.88 (2.03 to 7.41) <0.001 3.54 (2.17 to 5.75) <0.001
50-199 Referent
200-349 N/A N/A 0.58 (0.25 to 1.34) 0.206 0.19 (0.06 to 0.55) 0.002 0.74 (0.38 to 1.44) 0.376
≥350 N/A N/A N/A N/A 0.36 (0.12 to 1.09) 0.071 0.42 (0.15 to 1.17) 0.098
≥500 N/A N/A N/A N/A N/A N/A 0.42 (0.15 to 1.23) 0.115
Baseline viral load
(copies/ml)
<100 000 Referent
≥100 000 2.12 (0.86 to 5.21) 0.103 0.82 (0.44 to 1.53) 0.541 1.34 (0.77 to 2.33) 0.298 1.2 (0.78 to 1.85) 0.413
Current viral load
(copies/ml)
<400 Referent
400 – 9
999
N/A N/A 1.09 (0.44 to 2.66) 0.270 1.42 (0.57 to 3.59) 0.967 1.32 (0.56 to 3.14) 0.033
10 000 –
99 999
N/A N/A 0.64 (0.29 to 1.41) 0.106 1.02 (0.44 to 2.36) 0.394 2.24 (1.07 to 4.7) 0.001
≥100 000 N/A N/A 1.76 (0.89 to 3.47) 0.541 1.42 (0.63 to 3.2) 0.298 3.6 (1.68 to 7.7) 0.413
ART adherence
(quartiles)
<42% 2.14 (0.69 to 6.67) 0.188 1.89 (1 to 3.57) 0.049 1.40 (0.59 to 3.29) 0.443 2.21 (0.87 to 5.63) 0.096
42 to
75%
3.18 (1.05 to 9.61) 0.04 1.78 (0.92 to 3.43) 0.086 0.65 (0.26 to 1.64) 0.362 2.58 (1.04 to 6.39) 0.041
75 to
92%
N/A N/A 1.76 (0.9 to 3.46) 0.098 0.91 (0.37 to 2.23) 0.84 1.48 (0.56 to 3.91) 0.427
>92% Referent
ARV regimen First line Referent
Second
line
6.39 (0.85 to
47.75)
0.071 5.25 (2.11 to 13.06) <0.001 1.4 (0.64 to 3.06) 0.402 1.67 (1.09 to 2.56) 0.018
NNRTI in first line efavirenz Referent
neviripine 0.6 (0.28 to 1.26) 0.175 1.26 (0.8 to 2) 0.324 1.56 (0.85 to 2.85) 0.149 0.89 (0.59 to 1.34) 0.568
Duration of
monitoring prior to
starting ART
(months)
≥6 Referent
<6 2.9 (0.28 to 1.26) 0.296 1.15 (0.8 to 2) 0.692 1.67 (0.85 to 2.85) 0.328 1.05 (0.59 to 1.34) 0.890
Sex male 0.79 (0.38 to 1.67) 0.545 1 (0.68 to 1.46) 0.998 1.15 (0.69 to 1.91) 0.595 1.26 (0.85 to 1.86) 0.257
female Referent
Age at baseline
(years)
<25 0.63 (0.15 to 2.7) 0.531 2.06 (0.51 to 8.4) 0.312 1.82 (0.25 to 13.22) 0.555 2.15 (0.52 to 8.83) 0.289
25-49 Referent
≥50 1.69 (0.32 to 9.03) 0.540 2.39 (0.52 to 10.98) 0.263 1.34 (0.14 to 13.03) 0.801 3.86 (0.81 to 18.35) 0.090
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